SPOTLIGHT: Health plans target off-label use


Particularly given the rise of ultra-high-cost biologic drugs and other pricey treatments, health plans are intensifying their efforts to cut pharma costs. One way they're doing so, it seems, is to crack down on off-label prescribing, limiting coverage to only FDA-approved use for such drugs. The question, doctors say, is what to do if they believe that an off-label use is in their patient's best interest. Article

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.